Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AbbVie

3 Dividend Growth Stocks To Buy and Hold Forever

These three companies have a high 5-year dividend yield, providing long-term stability while maximizing income.

Barchart

How Is AbbVie's Stock Performance Compared to Other Pharmaceuticals Stocks?

AbbVie has outperformed the Pharmaceuticals industry over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

IBD Rating Upgrades: AbbVie Shows Improved Technical Strength

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Investors Business Daily

Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink?

AbbVie has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

AbbVie Stock: Using A Long-Term Leap Ratio Spread On This Pharma Giant

Positive post-earnings and a general upward draft of price action in the markets make for a strong argument for a bullish setup on AbbVie.

Investors Business Daily

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Tariffs Are About to Make Your Beauty Routine a Lot More Expensive

Here are the treatments that are most vulnerable to price hikes.

Marie Claire

If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio.

MarketBeat

AbbVie Hikes Its Outlook On The Back Of Two Powerhouse Drugs

AbbVie stock inched higher Friday after the pharma titan hiked its outlook on the back of strength from its immunology powerhouses.

Investors Business Daily

Earnings Preview: What to Expect From AbbVie's Report

AbbVie is scheduled to report its first-quarter results this month, with analysts anticipating a modest growth in earnings.

Barchart

3 Biopharmaceutical Stocks Bucking the Sell-Off

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

MarketBeat

Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan

Pharma names whipsawed Wednesday after Trump said he would enact "major" tariffs on drug imports and then backed off his tariffs — for now.

Investors Business Daily

Did pharma sector dodge Trump’s tariffs? The EU's not so sure

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

Euronews

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biotech Stocks Take A Tariffs Hit. Pharmaceuticals Are Exempt — For Now.

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe.

MarketBeat

AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock

Investors Business Daily

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Investors Business Daily

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

3 Top Dividend Kings to Scoop Up for Passive Income

Dividend Kings are good choices for reliable, low-risk investing.

MarketBeat

These Stocks Missed on Earnings, But Will Rebound Next Quarter

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

Barchart

Is Wall Street Bullish or Bearish on AbbVie Stock?

Despite AbbVie's underperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock's future.

Barchart

These 3 Dividend Aristocrats Could Be Your Best Investments This Year

Trying to make sense of market uncertainty? These 3 Dividend Aristocrats offer stability, strong yields & growth potential to help you weather 2025’s volatility.

Investors Business Daily

Top Dividend Stocks Yielding As High As 5%: Fidelity

Early in 2025, dividend stocks are swinging back into favor as the Federal Reserve cuts interest rates.

Barchart

Stocks Climb on Solid Corporate Earnings Results

The S&P 500 Index ($SPX ) (SPY ) today is up +0.67%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.32%. March E-mini S&P futures (ESH25 ) are up by +0.71%, and March E-mini Nasdaq...

Barchart

Stocks Retreat in Afternoon Trading

This afternoon, the S&P 500 Index ($SPX ) (SPY ) is down -0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.71%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up -0.36%. Stocks are moving lower this afternoon, after the Dow Jones Industrials posted an...

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.